Nivolumab-induced eosinophilic fasciitis: An unusual immune-related adverse event that needs to be recognized by practitioners

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy

(2022) Kimberly Tang et al.   JAMA Dermatology

Eosinophilic Fasciitis with Concurrent Necrobiotic Granulomatous Dermatitis Related to Checkpoint Inhibition Therapy

(2022) Adeeb Haroon et al.   Journal of Immunotherapy and Precision Oncology

Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy

(2021) Sri Harsha Boppana et al.   American Journal of Case Reports

Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature

(2019) Karmela Kim Chan et al.   ONCOLOGIST

Eosinophilic fasciitis: Current concepts

(2018) Nicole Fett et al.   CLINICS IN DERMATOLOGY

Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment

(2017) Daniel R. Mazori et al.   Current Rheumatology Reports